Perrigo, a pharmaceutical company, has agreed to buy Héra for €1.8 billion (US$2.1 billion), in a merger that would help cement Perrigo’s shift to focus on nonprescription drugs.
The all-cash acquisition of Héra would extend Dublin-based Perrigo’s presence in sales of blister-care, scar-care and women’s-health products. Héra, now co-owned by Astorg Partners, a private-equity firm, and by Goldman Sachs Asset Management, sells skin treatments such as Compeed and Mederma. It also makes ellaOne, an emergency contraceptive.
Buying Héra could boost Perrigo’s sales-growth trajectory and push along its transition to a deeper emphasis on nonprescription treatments, Chief Executive Murray Kessler said. Perrigo estimated on Wednesday, September 8, that the acquisition would add about €400 million, and about US$1 a share to its adjusted earnings in fiscal 2023.
The Héra acquisition “is a trade for what was volatile and declining earnings to growing extremely high-quality earnings,” Mr. Kessler said.
Héra gets a small portion of its revenue from prescription drugs. About 15% of Héra’s sales come from prescription products that treat rare diseases, Perrigo stated.
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
